PH23505A - Pharmaceutical suspension formulations containing cimetidine - Google Patents

Pharmaceutical suspension formulations containing cimetidine

Info

Publication number
PH23505A
PH23505A PH35588A PH35588A PH23505A PH 23505 A PH23505 A PH 23505A PH 35588 A PH35588 A PH 35588A PH 35588 A PH35588 A PH 35588A PH 23505 A PH23505 A PH 23505A
Authority
PH
Philippines
Prior art keywords
formulations containing
suspension formulations
pharmaceutical suspension
containing cimetidine
cimetidine
Prior art date
Application number
PH35588A
Other languages
English (en)
Inventor
Brian Anthony Carlin
John Norman Healey
Graham Stanley Leonard
Geoffrey David Tovey
Original Assignee
Smith Kline French Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Kline French Lab filed Critical Smith Kline French Lab
Publication of PH23505A publication Critical patent/PH23505A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PH35588A 1986-08-01 1987-07-28 Pharmaceutical suspension formulations containing cimetidine PH23505A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868618847A GB8618847D0 (en) 1986-08-01 1986-08-01 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
PH23505A true PH23505A (en) 1989-08-16

Family

ID=10602097

Family Applications (1)

Application Number Title Priority Date Filing Date
PH35588A PH23505A (en) 1986-08-01 1987-07-28 Pharmaceutical suspension formulations containing cimetidine

Country Status (22)

Country Link
US (1) US4996222A (fr)
EP (1) EP0257823B1 (fr)
JP (1) JPH0643304B2 (fr)
KR (1) KR960012397B1 (fr)
CN (1) CN1024497C (fr)
AU (1) AU601206B2 (fr)
CA (1) CA1287802C (fr)
DE (1) DE3778795D1 (fr)
DK (1) DK149988D0 (fr)
EG (1) EG18388A (fr)
ES (1) ES2037086T3 (fr)
GB (1) GB8618847D0 (fr)
GR (1) GR3005298T3 (fr)
HU (1) HU205853B (fr)
IE (1) IE60759B1 (fr)
IL (1) IL83349A (fr)
MY (1) MY100998A (fr)
PH (1) PH23505A (fr)
PT (1) PT85468B (fr)
WO (1) WO1988000825A1 (fr)
ZA (1) ZA875631B (fr)
ZW (1) ZW13587A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU196775B (en) * 1986-08-05 1989-01-30 Richter Gedeon Vegyeszet Process for production of morfologically unique new modifications of famotidin and medical compositions containing such substances
AU627775B2 (en) * 1988-09-20 1992-09-03 Glaxo Group Limited Pharmaceutical compositions
GB9127150D0 (en) * 1991-12-20 1992-02-19 Smithkline Beecham Plc Novel treatment
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
CA2121435C (fr) * 1993-04-16 2002-01-22 Sheila M. Ratnaraj Suspension pharmaceutique aqueuse et methode de preparation
AU3154895A (en) * 1994-08-01 1996-03-04 Kv Pharmaceutical Corporation Tastemasked liquid pharmaceutical delivery system
GB9504599D0 (en) * 1995-03-03 1995-04-26 Reckitt & Colmann Prod Ltd Improvements in or relating to organic compositions
GB2298365B (en) * 1995-03-03 1997-05-07 Reckitt & Colmann Prod Ltd A liquid pharmaceutical composition alginate and potassium bicarbonate
GB9708772D0 (en) * 1997-04-30 1997-06-25 Reckitt & Colmann Prod Ltd Organic compositions
CN1286468C (zh) * 1997-04-30 2006-11-29 雷克特本克斯尔保健(英国)有限公司 含藻酸或藻酸盐的药物组合物
IN186245B (fr) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US6287693B1 (en) 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
US6132758A (en) * 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
GB9930058D0 (en) * 1999-12-20 2000-02-09 Novartis Ag Organic compounds
US6515008B1 (en) * 2000-05-04 2003-02-04 Smithkline Beecham Corporation Formulation
DE10224086A1 (de) * 2002-05-31 2003-12-11 Bayer Ag Pharmazeutische Zubereitungen zur oralen Anwendung enthaltend wirkstoffbeladene Ionentauscherharze sowie strukturviskose Gelbildner als Verdicker
US6930119B2 (en) * 2002-07-17 2005-08-16 Reliant Pharmaceuticals, Inc. Liquid pharmaceutical composition
EP1603579A4 (fr) * 2003-03-10 2006-06-14 Univ Michigan Compositions et methodes d'utilisation de produits d'obturation durale a base d'alginate
US20080095901A1 (en) * 2004-11-02 2008-04-24 Purac Biochem B.V> Method for Stabilizing and Preventing Coagulation of Proteins in Milk
US20060094760A1 (en) * 2004-11-04 2006-05-04 Fawzy Abdel A Composition, system and method of treatment of gastrointestinal disorders with nizatidine oral solution
EP1745775B1 (fr) * 2005-07-19 2008-05-28 Ethypharm Formulations de rétention gastrique et procédé de préparation
FR2911506B1 (fr) * 2007-01-18 2009-07-03 Ceva Sante Animale Sa Compositions pharmaceutiques destinees a une administration par voie orale sous forme de suspensions aqueuses stabilisees
US8999395B2 (en) * 2007-02-09 2015-04-07 Ceva Sante Animale Pharmaceutical compositions for oral administration in the form of stabilised aqueous suspensions
WO2011031176A1 (fr) * 2009-09-10 2011-03-17 Bial - Portela & C.A., S.A. Formulations de suspension orales d’acétate d’eslicarbazépine
CN111481508A (zh) * 2016-10-19 2020-08-04 萨恩帕斯药物有限公司 针对引起离子通道病的药物的保护性组合物和方法
GB201918617D0 (en) * 2019-12-17 2020-01-29 Reckitt Benckiser Health Ltd Personal lubricant composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56104868A (en) * 1980-01-24 1981-08-20 Fujimoto Seiyaku Kk Conversion between polymorphous crystals of cimetidine
HU185457B (en) * 1981-09-25 1985-02-28 Richter Gedeon Vegyeszet Process for preparating cimetidine-z
CA1239349A (fr) * 1983-10-10 1988-07-19 Eberhard F. Gottwald Compose pharmaceutique contenant de la cimetidine

Also Published As

Publication number Publication date
AU7756487A (en) 1988-02-24
CN1024497C (zh) 1994-05-18
DE3778795D1 (de) 1992-06-11
EG18388A (en) 1992-10-30
ES2037086T3 (es) 1993-06-16
DK149988A (da) 1988-03-18
HU205853B (en) 1992-07-28
JPH0643304B2 (ja) 1994-06-08
WO1988000825A1 (fr) 1988-02-11
US4996222A (en) 1991-02-26
PT85468A (en) 1987-08-01
PT85468B (pt) 1990-06-29
AU601206B2 (en) 1990-09-06
GR3005298T3 (fr) 1993-05-24
IE872077L (en) 1988-02-01
KR880701551A (ko) 1988-11-03
GB8618847D0 (en) 1986-09-10
DK149988D0 (da) 1988-03-18
EP0257823A1 (fr) 1988-03-02
ZA875631B (en) 1989-03-29
JPH01500434A (ja) 1989-02-16
EP0257823B1 (fr) 1992-05-06
IL83349A (en) 1992-03-29
CN87105387A (zh) 1988-02-17
ZW13587A1 (en) 1989-02-15
MY100998A (en) 1991-06-29
CA1287802C (fr) 1991-08-20
IE60759B1 (en) 1994-08-10
HUT46541A (en) 1988-11-28
KR960012397B1 (ko) 1996-09-20

Similar Documents

Publication Publication Date Title
PH23505A (en) Pharmaceutical suspension formulations containing cimetidine
GB2211413B (en) Pharmaceutical formulations comprising microcapsules
GB8716904D0 (en) Stable pharmaceutical preparation
GB8619432D0 (en) Pharmaceutical compounds
CS8700282A2 (en) Nicorandil-containing stable pharmaceutical
GB2187953B (en) Pharmaceutical formulation
GB8707256D0 (en) Compounds & pharmaceutical preparations
GB8623389D0 (en) Pharmaceutical formulations
ZA876048B (en) Pharmaceutical formulation
GR871915B (en) Pharmaceutical formulations
ZA875937B (en) Pharmaceutical formulations comprising microcapsules
GB8503221D0 (en) Pharmaceutical formulations
ZA875281B (en) Zylometzoline-containing pharmaceutical preparations
GB8603097D0 (en) Pharmaceutical formulations
ZA876959B (en) Pharmaceutical formulations
IL91357A0 (en) Pharmaceutical formulations containing certain benzimi-azolylmethyl benzenamides
GB8419107D0 (en) Pharmaceutical formulations
GB8421737D0 (en) Pharmaceutical formulations
GB8421741D0 (en) Pharmaceutical formulations
GB8521863D0 (en) Pharmaceutical formulations
BG43026A1 (en) Lyposomic pharmaceutical form
GB8630769D0 (en) Pharmaceutical formulation
GB8624269D0 (en) Pharmaceutical formulation
GB8604244D0 (en) Pharmaceutical formulation
GB8630904D0 (en) Pharmaceutical formulation